Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections

International Journal of Antimicrobial Agents

Volumn 44, Issue 5, 2014, Pages 409-415

  Luque, S ^a   Grau, S ^a,b   Alvarez Lerma, F ^a   Ferrandez O ^a   Campillo, N ^a   Horcajada, J P ^a   Basas, M ^a   Lipman, J ^c,d   Roberts, J A ^c,d  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Central nervous system; Cerebrospinal fluid; Critically ill patients; Infection; Linezolid; Pharmacokinetics

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID DRAINAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NEUROSURGERY; STEADY STATE; BLOOD; CENTRAL NERVOUS SYSTEM INFECTIONS; CEREBROSPINAL FLUID; CHEMISTRY; CRITICAL ILLNESS; PLASMA; PROSPECTIVE STUDY;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; CENTRAL NERVOUS SYSTEM INFECTIONS; CEREBROSPINAL FLUID; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROSURGERY; OXAZOLIDINONES; PLASMA; PROSPECTIVE STUDIES;

EID: 84908416544     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.07.001     Document Type: Article

References (30)

1. Estudio Nacional de Vigilancia de Infección Nosocomial en Servicios de Medicina Intensiva (ENVIN-HELICS) Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC), Grupo de Trabajo de Enfermedades Infecciosas 2012 ENVIN-HELICS http://hws.vhebron.net/envin-helics/Help/Informe%20ENVIN-UCI%202012.pdf [accessed 16 January 2014]
2. Hospital del Mar, Parc de Salut Mar Protocols i procedimients d'infermeria, Malalt neurocritic 2010 Hospital del Mar, Parc de Salut Mar
3. P. Viale, L. Pagani, F. Cristini, R. Stefini, R. Bergomi, and P. Colombini Linezolid for the treatment of central nervous system infections in neurosurgical patients Scand J Infect Dis 34 2002 456 459
4. P. Villani, M.B. Regazzi, F. Marubbi, P. Viale, L. Pagani, and F. Cristini Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections Antimicrob Agents Chemother 46 2002 936 937
5. R. Beer, B. Pfausler, and E. Schmutzhard Management of nosocomial external ventricular drain-related ventriculomeningitis Neurocrit Care 10 2009 363 367
6. D. Hoefnagel, R. Dammers, M.P. Ter Laak-Poort, and C.J. Avezaat Risk factors for infections related to external ventricular drainage Acta Neurochir (Wien) 150 2008 209 214
7. M.E. Jiménez-Mejías, and E. García-Cabrera Infection of cerebrospinal fluid shunt systems Enferm Infecc Microbiol Clin 26 2008 240 251 [in Spanish]
8. Y.Q. Xiong, M.R. Yeaman, and A.S. Bayer Linezolid: a new antibiotic Drugs Today (Barc) 36 2000 631 639
9. S. Sabbatani, R. Manfredi, G. Frank, and F. Chiodo Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds Infez Med 13 2005 112 119
10. T.A. Rupprecht, and H.W. Pfister Clinical experience with linezolid for the treatment of central nervous system infections Eur J Neurol 12 2005 536 542
11. R. Nau, F. Sörgel, and H. Eiffert Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections Clin Microbiol Rev 23 2010 858 883
12. P. Myrianthefs, S.L. Markantonis, K. Vlachos, M. Anagnostaki, E. Boutzouka, and D. Panidis Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients Antimicrob Agents Chemother 50 2006 3971 3976
13. R. Beer, K.W. Engelhardt, B. Pfausler, G. Broessner, R. Helbok, and P. Lackner Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains Antimicrob Agents Chemother 51 2007 379 382
14. B. Viaggi, A.D. Paolo, R. Danesi, M. Polillo, L. Ciofi, and M. Del Tacca Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics Scand J Infect Dis 43 2011 721 727
15. Y. Tsuji, Y. Hiraki, K. Matsumoto, A. Mizoguchi, S. Sadoh, and T. Kobayashi Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitis Scand J Infect Dis 43 2011 982 985
16. P. Malacarne, B. Viaggi, A. Di Paolo, R. Danesi, and M. Del Tacca Linezolid cerebrospinal fluid concentration in central nervous system infection J Chemother 19 2007 90 93
17. J.A. Roberts Using PK/PD to optimize antibiotic dosing for critically ill patients Curr Pharm Biotechnol 12 2011 2070 2079
18. D.J. Stalker, and G.L. Jungbluth Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial Clin Pharmacokinet 42 2003 1129 1140
19. C.R. Rayner, A. Forrest, A.K. Meagher, M.C. Birmingham, and J.J. Schentag Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme Clin Pharmacokinet 42 2003 1411 1423
20. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/Breakpoint-table-v-4.0.pdf [accessed 16 January 2014].
21. F. Pea, M. Furlanut, P. Cojutti, F. Cristini, E. Zamparini, and L. Franceschi Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis Antimicrob Agents Chemother 54 2010 4605 4610
22. S.L. Beal, L.B. Sheiner, A.J. Boeckmann, and R.J. Bauer NONMEM 7.2.0 Users Guides 1989-2011 Icon Development Solutions Ellicott City, MD ftp://nonmem.iconplc.com/Public/nonmem720/guides
23. J. Parke, N.H. Holford, and B.G. Charles A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models Comput Methods Programs Biomed 59 1999 19 29
24. A.P. MacGowan Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections J Antimicrob Chemother 51 2003 ii17 ii25
25. L.M. Boak, J. Li, D. Spelman, P. du Cros, R.L. Nation, and C.R. Rayner Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis Ann Pharmacother 40 2006 1451 1455
26. C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, and C. Kloft Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis Antimicrob Agents Chemother 50 2006 2455 2463
27. N. Plock, C. Buerger, C. Joukhadar, S. Kljucar, and C. Kloft Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients Drug Metab Dispos 35 2007 1816 1823
28. L. Morata, M. Cuesta, J.F. Rojas, S. Rodriguez, M. Brunet, and G. Casals Risk factors for a low linezolid trough plasma concentration in acute infections Antimicrob Agents Chemother 57 2013 1913 1917
29. J.A. Roberts, and J. Lipman Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility Crit Care Med 41 2013 489 495
30. A.A. Udy, J.A. Roberts, and J. Lipman Clinical implications of antibiotic pharmacokinetic principles in the critically ill Intensive Care Med 39 2013 2070 2082